Skip to main content

Advertisement

SpringerLink
Log in

Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy

  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

We discuss two cases receiving different anti-tumornecrosis-factor alpha antagonists (anti-TNF-α); one for psoriatic arthritis (PA) and the other for ankylosing spondylitis (AS). Due to neurological symptoms cerebral magnetic resonance imaging (MRI) was performed and cerebral lesions were detected. Our interpretations of these cerebral lesions and the resulting diagnostic and therapeutic consequences are presented in regard of data published in the medical literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barkhof F, Filippi M, Miller DH, ScheltensP, Campi A, Polman CH, Comi G,Adèr HJ, Losseff N, Valk J (1997) Comparisonof MRI criteria at first presentationto predict conversion to clinicallydefinite multiple sclerosis. Brain120:2059–2069

    Article  PubMed  Google Scholar 

  2. Bellesi M, Logullo F, DiBella P, ProvincialiL (2006) CNS demyelination duringanti-tumor necrosis factor alphatherapy. J Neurol 253:668–669

    Article  PubMed  Google Scholar 

  3. Bensouda-Grimaldi L, Mullemann D,Valat JP, Autret-leca E (2007) Adalimumab-associated Multiple Sclerosis.J Rheumatol 34:239–240

    PubMed  Google Scholar 

  4. Calin A (1989) Is there an associationbetween ankylosing spondylitis andmultiple sclerosis? Ann Rheum Dis48:971–972

    Article  PubMed  CAS  Google Scholar 

  5. Cellerini M, Gabbrielli S, Bongi SM(2001) Cerebral magnetic resonanceimaging in a patient with ankylosingspondylitis and multiple sclerosis-likesyndrome. Neuroradiology 43:1067–1069

    Article  PubMed  CAS  Google Scholar 

  6. Enayati PJ, Papadakis KA (2005) Associationof anti-tumor necrosis factortherapy with the development ofmultiple sclerosis. J Clin Gastroenterol39:303–306

    Article  PubMed  Google Scholar 

  7. Foroozan R, Buono LM, Sergott RC,Savino PJ (2002) Retrobulbar opticneuritis associated with infliximab.Arch Ophthalmol 120:985–987

    PubMed  Google Scholar 

  8. Fox DA (2000) Cytokine blockade as anew strategy to treat rheumatoidarthritis. Inhibition of tumor necrosisfactor. Arch Intern Med 160:437–444

    Article  PubMed  CAS  Google Scholar 

  9. Gupta G, Gelfand JM, Lewis JD (2005)Increased risk for demyelinating diseasesin patients with inflammatorybowel disease. Gastroenterology 129:1117–1120

    Article  Google Scholar 

  10. Hemmer B, Hartung HP (2007)Towards the development of rationaltherapies in multiple sclerosis: What ison the horizon? Ann Neurol 62:314–326

    Article  PubMed  CAS  Google Scholar 

  11. Jarand J, Zochodne DW, Martin LO,Voll C (2006) Neurological complicationsof infliximab. J Rheumatol 33:1018–1020

    PubMed  Google Scholar 

  12. Kelley RE (2006) Ischemic demyelination.Neurol Res 28:334–340

    Article  PubMed  Google Scholar 

  13. Kim E, Edgar E, Isenhath S, Blauwelt A,Bourdette D, Whitham R (2008)Successful treatment of pyodermagangrenosum with a TNF-alphablocker in a subject with multiplesclerosis. Neurology 70(Suppl 1):A93

    Google Scholar 

  14. Kimura K, Hunter SF, Thollander MS,Loftus EV Jr, Melton LJ 3rd, O’BrienPC, Rodriguez M, Phillips SF (2000)Concurrence of inflammatory boweldisease and multiple sclerosis. MayoClin Proc 75:802–806

    CAS  Google Scholar 

  15. Kodama S, Davis M, Faustmann DL(2005) The therapeutic potential oftumor necrosis factor for autoimmunedisease: a mechanistically basedhypothesis. Cell Mol Lif Sci 62:1850–1862

    Article  CAS  Google Scholar 

  16. Magnano MD, Robinson WH, GenoveseMC (2004) Demyelination andinhibition of tumor necrosis factor(TNF). Clin Exp Rheumatol 22(5 Suppl35):S134–S140

    PubMed  CAS  Google Scholar 

  17. Marotte H, Charrin JE, Miossec P(2002) Infliximab-induced asepticmeningitis. Lancet 359:1252

    Google Scholar 

  18. McDonald WI, Compston A, Edan G,Goodkin D, Hartung HP, Lublin FD,McFarland HF, Paty DW, Polman CH,Reingold SC, Sandberg-Wollheim M,Sibley W, Thompson A, van den NoortS, Weinshenker BY, Wolinsky JS (2001)Recommended diagnostic criteria formultiple sclerosis: guidelines from theInternational Panel on the diagnosis ofmultiple sclerosis. Ann Neurol 50:121–127

    Article  PubMed  CAS  Google Scholar 

  19. Midgard R, Grønning M, Riise T, KvåleG, Nyland H (1996) Multiple sclerosisand chronic inflammatory diseases. Acase-control study. Acta Neurol Scand93:322–328

    Article  PubMed  CAS  Google Scholar 

  20. Mohan N, Edwards ET, Cupps TR,Oliviero PJ, Sandberg G, Crayton H,Richert JR, Siegel JN (2001) Demyelinationoccuring during anti-tumornecrosis factor alpha therapy forinflammatory arthritides. ArthritisRheum 44:2862–2869

    CAS  Google Scholar 

  21. Quispel R, van der Worp HB, PruissenM, Schipper ME, Oldenburg B (2006)Fatal aseptic meningoencephalitisfollowing infliximab treatment for inflammatorybowel disease. Gut 55:1056

    Article  PubMed  CAS  Google Scholar 

  22. Ramagopalan SV, Dyment DA, ValdarW, Herrera BM, Criscuoli M, Yee IM,Sadovnick AD, Ebers GC; CanadianCollaborative Study Group (2007)Autoimmune disease in families withmultiple sclerosis: a population-basedstudy. Lancet Neurol 6:604–610

    Article  PubMed  Google Scholar 

  23. Ranges GE, Figari IS, Espevik T, PalladinoMA (1987) Inhibition of cytotoxicT cell development by transforminggrowth factor-beta and reversakl byrecombinant tumor necrosis factoralpha. J Exp Med 166:991–999

    Article  PubMed  CAS  Google Scholar 

  24. Reidel MA, Stippich C, Heiland S,Storch-Hagenlocher B, Jansen O,Hähnel S (2003) Differentiation ofmultiple sclerosis plaques, subacutecerebral ischaemic infarcts, focalvasogenic oedema and lesions of subcorticalarteriosclerotic encephalopathyusing magnetisation transfer measurements.Neuroradiology 45:289–294

    PubMed  CAS  Google Scholar 

  25. Selmaj KW, Raine CS (1988) Tumor necrosisfactor mediates myelin and oligodendrocytedamage in vitro. AnnNeurol 23:339–346

    CAS  Google Scholar 

  26. Selmaj KW, Raine CS (1995) Experimentalautoimmune encephalomyelitis:immunotherapy with anti-tumornecrosis factor antibodies and solubletumor necrosis factor receptors. Neurology45(Suppl 6):S44–S49

    PubMed  CAS  Google Scholar 

  27. Selmaj KW (2000) Tumour necrosisfactor and anti-tumour necrosis factorapproach to inflammatory demyelinatingdiseases of the central nervous system.Ann Rheum Dis 59(Suppl I):i94–i102

    Article  PubMed  CAS  Google Scholar 

  28. Shin IS, Baer AN, Kwon HJ, PapadopoulosEJ, Siegel JN (2006) Guillain-Barré and Miller Fisher syndromesoccurring with tumor necrosis factoralpha antogonist therapy. ArthritisRheum 54:1429–1434

    CAS  Google Scholar 

  29. Sicotte NL, Voskuhl RR (2001) Onset ofmultiple sclerosis associated with anti-TNF therapy. Neurology 57:1885–1888

    PubMed  CAS  Google Scholar 

  30. Tan FU, Tellioğlu S, Aydin G,Erdemoğlu AK, Keles¸ I (2004) Ankylosingspondylitis and multiple sclerosisin a HLA-B27 negative patient. ActaNeurol Belg 104:169–172

    Google Scholar 

  31. Tanno M, Nakamura I, Kobayashi S,Kurihara K, Ito K (2006) New-onsetdemyelination induced by infliximabtherapy in two rheumatoid arthritispatients. Clin Rheumatol 25:929–933

    Article  PubMed  Google Scholar 

  32. The Lenercept Multiple Sclerosis StudyGroup and the University of BritishColumbia MS/MRI Analysis Group(1999) TNF neutralization in multiplesclerosis: results of a randomized,placebo-controlled multicenter study.Neurology 53:457–465

    Google Scholar 

  33. Thomas CW Jr, Weinshenker BG, SandbornWJ (2004) Demyelination duringanti-tumor necrosis factor alpha therapywith infliximab for Crohn’s disease.Inflamm Bowel Dis 10:28–31

    Article  PubMed  Google Scholar 

  34. Titelbaum DS, Degenhardt A, KinkelRP (2005) Anti-tumor necrosis factoralpha-associated Multiple Sclerosis.Am J Neuroradiol 26:1548–1550

    PubMed  Google Scholar 

  35. Toussirot E, Pertuiset E, Martin A,Melac-Ducamp S, Alcalay M, Grardel B,Seror P, Perdriger A, Wendling D,Mulleman D, Beraneck L, Mariette X;Club Rheumatismes et Inflammation(2006) Association of rheumatoidarthritis with multiple sclerosis: reportof 14 cases and discussion of its significance.J Rheumatol 33:1027–1028

    PubMed  Google Scholar 

  36. Van Oosten BW, Barkhof F, Truyen L,Boringa JB, Berteslmann FW, vonBolmberg BM, Woody JN, Hartung HP,Polman CH (1996) Increased MRIactivity and immune activation in twomultiple sclerosis patients treated withthe monoclonal anti-tumor necrosisfactor antibody cA2. Neurology 47:1531–1534

    PubMed  CAS  Google Scholar 

  37. Yokota S, Geppert TD, Lipsky PI (1988)Enhancement of antigen-and mitogen-inducedhuman T lymphocyte proliferationby tumor necrosis factor.J Immunol 140:531–538

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, University of Rostock, Gehlsheimer Strasse 20, 18147, Rostock, Germany

    Alexander Winkelmann, Robert Patejdl, Reiner Benecke & Uwe Klaus Zettl

  2. Institute for Diagnostic and Interventionell Radiology, University of Rostock, Rostock, Germany

    Sabine Wagner

Authors
  1. Alexander Winkelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Patejdl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabine Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reiner Benecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uwe Klaus Zettl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Winkelmann.

Additional information

Conflict of interest We have no conflicts of interest.

Disclosure We have nothing to disclose.

Role of the funding source No funding sources were involved in the preparation of this article or in the decision to submit it for publication.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winkelmann, A., Patejdl, R., Wagner, S. et al. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 255 (Suppl 6), 109–114 (2008). https://doi.org/10.1007/s00415-008-6020-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-6020-z

Key words

Search

Navigation